Get the Stockscreener App
37.72
0.41%
-0.2071
Cogent Biosciences Inc stock is traded at $37.72, with a volume of 843.49K.
It is down -0.41% in the last 24 hours and down -3.34% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$37.93
Open:
$37.95
24h Volume:
843.49K
Relative Volume:
0.34
Market Cap:
$6.55B
Revenue:
-
Net Income/Loss:
$-354.30M
P/E Ratio:
-14.95
EPS:
-2.5234
Net Cash Flow:
$-286.27M
1W Performance:
-9.04%
1M Performance:
-3.34%
6M Performance:
+0.41%
1Y Performance:
+217.69%
1-Day Range:
$37.51
$38.10
1-Week Range:
$36.57
$40.85
52-Week Range:
$11.53
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
37.73 | 6.58B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences set to report earnings ahead of FDA decisions By Investing.com - Investing.com Canada
Cogent Biosciences set to report earnings ahead of FDA decisions - Investing.com
Is Cogent Biosciences Inc (COGT) Worth the Risk After Q2 Earnings Miss? GF Score: 25/100 - GuruFocus
Form 8K Cogent Biosciences Inc For: 10 August By Investing.com - Investing.com Australia
Cogent Biosciences Q2 EPS of $(0.52) beats estimates by 8.77% - scanx.trade
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results - MarketBeat
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, Vs. FactSet Est of $98M Loss - moomoo.com
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach - Quiver Quantitative
Cogent Biosciences Q2 net loss widens on higher expenses - TradingView
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib - Stock Titan
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. - Stock Titan
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Cogent Biosciences (COGT) Earnings Date and Reports 2026 - MarketBeat
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Loss-Making Cogent Biosciences, Inc. (NASDAQ:COGT) Expected To Breakeven In The Medium-Term - Moomoo
Cogent Biosciences (COGT) Stock Analysis: High Potential with 29.78% Upside and Strong Buy Ratings - directorstalkinterviews.com
Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts - Quiver Quantitative
Defilade Capital Management L.P. Sells 216,029 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Seven Fleet Capital Management LP Sells 64,700 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis: A Biotech with Promising Upside and Analyst Confidence - directorstalkinterviews.com
Principal Financial Group Inc. Trims Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Redmile Group LLC Decreases Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Projected to Release Earnings on Tuesday - MarketBeat
BlackRock (COGT holder) discloses 8.0% ownership in Cogent Biosciences common stock - Stock Titan
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cogent Biosciences Inc (COGT) Cash Flow - TradingKey
COGT|Cogent Biosciences Inc|Price:40.450|Chg%:+0.690 - TradingKey
Sona Asset Management US LLC Decreases Position in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT|Cogent Biosciences Inc|Price:38.705|Chg%:+0.005 - TradingKey
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cogent Biosciences Inc Stock (COGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):